Hypoxia Induced High Expression of Thioredoxin Interacting Protein (TXNIP) in Non-small Cell Lung Cancer and its Prognostic Effect

  • Li, Yan (Department of Respiratory Medicine, the Affiliated Drum Tower Hospital of Nanjing University Medical School) ;
  • Miao, Li-Yun (Department of Respiratory Medicine, the Affiliated Drum Tower Hospital of Nanjing University Medical School) ;
  • Xiao, Yong-Long (Department of Respiratory Medicine, the Affiliated Drum Tower Hospital of Nanjing University Medical School) ;
  • Huang, Mei (Department of Respiratory Medicine, the Affiliated Drum Tower Hospital of Nanjing University Medical School) ;
  • Yu, Min (Department of Respiratory Medicine, the Affiliated Drum Tower Hospital of Nanjing University Medical School) ;
  • Meng, Kui (Department of Pathology, the Affiliated Drum Tower Hospital of Nanjing University Medical School) ;
  • Cai, Hou-Rong (Department of Respiratory Medicine, the Affiliated Drum Tower Hospital of Nanjing University Medical School)
  • Published : 2015.04.14


Although associations between thioredoxin interacting protein (TXNIP) and cancers have been recognized, the effects of TXNIP on non-small cell lung cancer (NSCLC) prognosis remained to be determined in detail. In addition, while hypoxia is a key characteristic of tumor cell growth microenvironment, the effect of hypoxia on TXNIP expression is controversial. In this study, formaldehyde fixed and paraffin embedded (FFPE) samples of 70 NSCLC patients who underwent resection between January 2010 and December 2011 were obtained. Evaluation of TXNIP and hypoxia inducible factor-$1{\alpha}$ ($HIF-1{\alpha}$) protein expression in FFPE samples was made by immunohistochemistry. By Kaplan-Meier method, patients with high TXNIP expression demonstrated a significantly shorter progression free survival (PFS) compared with those with low TXNIP expression (18.0 months, 95%CI: 11.7, 24.3 versus 23.0 months, 95%CI: 17.6, 28.4, P=0.02). High TXNIP expression level was also identified as an independent prognostic factor by Cox regression analysis (adjusted hazard ratio: 2.46; 95%CI: 1.08, 5.56; P=0.03). Furthermore, TXNIP expression was found to be significantly correlated with $HIF-1{\alpha}$ expression (Spearman correlation=0.67, P=0.000). To further confirm correlations, we established a tumor cell hypoxic culture model. Expression of TXNIP was up-regulated in all three NSCLC cell lines (A549, SPC-A1, and H1299) under hypoxic conditions. This study suggests that hypoxia induces increased TXNIP expression in NSCLC and high TXNIP expression could be a poor prognostic marker.


Thioredoxin interacting protein;hypoxia inducible factor-$1{\alpha}$;survival;prognosis


Supported by : Natural Science Foundation of Jiangsu Province


  1. Ahsan MK, Masutani H, Yamaguchi Y, et al (2006). Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2. Oncogene, 25, 2181-91.
  2. Aitken CJ, Hodge JM, Nishinaka Y, et al (2004). Regulation of human osteoclast differentiation by thioredoxin binding protein-2 and redox-sensitive signaling. J Bone Miner Res, 19, 2057-64.
  3. Baker AF, Koh MY, Williams RR, et al (2008). Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas, 36, 178-86.
  4. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001). The new World Health Organization classification of lung tumours. Eur Respir J, 18, 1059-68.
  5. Butler LM, Zhou X, Xu WS, et al (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA, 99, 11700-5.
  6. Chen J, Hui ST, Couto FM, et al (2008). Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic $\beta$-cell mass and protects against diabetes. FASEB J, 22, 3581-94.
  7. Chen KS, DeLuca HF (1994). Isolation and characterization of a novel cDNA from HL-60 cells treated with 1, 25-dihydroxyvitamin D-3. Biochim Biophys Acta, 1219, 26-32.
  8. Corbett JA (2008). Thioredoxin-interacting protein is killing my beta-cells!. Diabetes, 57, 797-8.
  9. Fraga A, Ribeiro R, Medeiros R (2009). Tumor hypoxia: the role of HIF. Actas Urol Esp, 33, 941-51.
  10. Goldstraw P, Crowley J, Chansky K, et al (2007). The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 706-14.
  11. Junn E, Han SH, Im JY, et al (2000). Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol, 164, 6287-95.
  12. Karar J, Dolt KS, Mishra MK, et al (2007). Expression and functional activity of pro-oxidants and antioxidants in murine heart exposed to acute hypobaric hypoxia. FEBS Lett, 581, 4577-82.
  13. Lee KN, Kang HS, Jeon JH, et al (2005). VDUP1 is required for the development of natural killer cells. Immunity, 22, 195-208.
  14. Le Jan S, Le Meur N, Cazes A, et al (2006). Characterization of the expression of the hypoxia-induced genes neuritin, TXNIP and IGFBP3 in cancer. FEBS Lett, 580, 3395-400.
  15. Masutani H, Yoshihara E, Masaki S, Chen Z, Yodoi J (2012). Thioredoxin binding protein (TBP)-2/Txnip and $\alpha$-arrestin proteins in cancer and diabetes mellitus. J Clin Biochem Nutr, 50, 23-34.
  16. Oka S, Yoshihara E, Bizen-Abe A, et al (2009). Thioredoxin binding protein-2/thioredoxin-interacting protein is a critical regulator of insulin secretion and peroxisome proliferatoractivated receptor function. Endocrinology, 150, 1225-34.
  17. Ping W, Jiang WY, Chen WS, Sun W, Fu XN (2013). Expression and significance of hypoxia inducible factor-$1{\alpha}$ and lysyl oxidase in non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 3613-8.
  18. Semenza GL (2011). Hypoxia. Cross talk between oxygen sensing and the cell cycle machinery. Am J Physiol Cell Physiol, 301, 550-2.
  19. Semenza GL, Wang GL (1992). A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 12, 5447-54.
  20. Semenza GL (2011). Regulation of metabolism by hypoxiainducible factor 1. Cold Spring Harb Symp Quant Biol, 76, 347.
  21. Shi S, Wang R, Chen Y, et al (2013). Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS One, 8, 65757.
  22. Shin D, Jeon JH, Jeong M, et al (2008). VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta, 1783, 838-48.
  23. Wang Q, Hu DF, Rui Y, et al (2014). Prognosis value of HIF-$1{\alpha}$ expression in patients with non-small cell lung cancer. Gene, 541, 69-74.
  24. Wong RW, Hagen T (2013). Mechanistic target of rapamycin (mTOR) dependent regulation of thioredoxin interacting protein (TXNIP) transcription in hypoxia. Biochem Biophys Res Commun, 433, 40-6.
  25. World C, Spindel ON, Berk BC (2011). Thioredoxin-interacting protein mediates TRX1 translocation to the plasma membrane in response to tumor necrosis factor-$\alpha$: a key mechanism for vascular endothelial growth factor receptor-2 transactivation by reactive oxygen species. Arterioscler Thromb Vasc Biol, 31, 1890-7.
  26. Yoshioka J, Schreiter ER, Lee RT (2006). Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal, 8, 2143-51.

Cited by

  1. Significance of Tissue Expression and Serum Levels of Angiopoietin-like Protein 4 in Breast Cancer Progression: Link to NF-κB /P65 Activity and Pro-Inflammatory Cytokines vol.16, pp.18, 2016,
  2. Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP pp.1476-5594, 2018,
  3. Comparing atmospheric and hypoxic cultured mesenchymal stem cell transcriptome: implication for stem cell therapies targeting intervertebral discs vol.16, pp.1, 2018,